Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis
- 29 May 2019
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 78 (9), 1186-1191
- https://doi.org/10.1136/annrheumdis-2018-214894
Abstract
Objective To compare the effects of interleukin-6 (IL-6) receptor and tumour necrosis factor inhibition on inducing repair of existing bone erosions in patients with very early rheumatoid arthritis (RA). Methods Prospective non-randomised observational study in patients with active erosive RA with inadequate response to methotrexate (MTX) receiving either tocilizumab (TOC) monotherapy or adalimumab (ADA) with MTX for 52 weeks. Erosion volumes were assessed in metacarpal heads (MCH) and the radius by high-resolution peripheral quantitative CT at baseline and after 52 weeks. Clinical response was monitored using Clinical Disease Activity Index, Simple Disease Activity Index and Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) scores every 12 weeks. Results TOC (N=33) and ADA/MTX (N=33) treatment groups were balanced for age, sex, body mass index, comorbidities, disease and activity, functional state, autoantibody status, baseline bone damage and baseline bone biomarkers. Both TOC (DAS28-ESR: baseline: 6.2±0.5; 52 weeks: 2.3±1.0) and ADA/MTX (6.3±0.6; 2.8±1.2) significantly reduced disease activity. Erosion volumes significantly decreased in the MCH and radius of patients with RA treated with TOC (p3 and −3.3±5.9 mm3 in the MCH and radius of TOC-treated patients, respectively, and −0.05±0.9 mm3 and −0.08±4.1 mm3 in patients treated with ADA/MTX. Conclusions The REBONE study shows that TOC monotherapy achieves more pronounced repair of existing bone erosions than ADA/MTX. Hence, IL-6 is a central factor for the disturbed bone homeostasis in the joints of patients with RA.Keywords
This publication has 24 references indexed in Scilit:
- How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomyNature Medicine, 2013
- Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatmentNature Reviews Rheumatology, 2012
- Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT studyAnnals Of The Rheumatic Diseases, 2012
- Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentinJCI Insight, 2012
- The Pathogenesis of Rheumatoid ArthritisNew England Journal of Medicine, 2011
- Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destructionAnnals Of The Rheumatic Diseases, 2011
- Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosionAnnals Of The Rheumatic Diseases, 2011
- Inhibition of interleukin‐6 receptor directly blocks osteoclast formation in vitro and in vivoArthritis & Rheumatism, 2009
- Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti–tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy studyArthritis & Rheumatism, 2005
- TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligandJCI Insight, 2000